Exelixis Announces Third Quarter 2013 Financial Results

04-11-2013 Business Wire HealthComments (0)


Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended September 30, 2013. Q3 2013 Highlights and Recent Events Reported net product revenue for COMETRIQ® (cabozantinib) of $4.8 million in the third quarter of 2013. Reached the enrollment target of 960 patients for COMET-1, the phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of COMET-1

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top